Article
HTA Quarterly Summer 2025
In this edition, our experts explore the health technology assessment (HTA) process and policies in Japan, describe early access program (EAP) pathways in France (in the first of a three-part series of articles on this topic), and consider potential impacts of the Joint Clinical Assessment (JCA) and Project Orbis on revenue generation for new medicinal products in oncology.
Heard on the street
“If the JCA could help build a European market, accelerating the process and allowing developers to save one or two years after marketing approval, that is what would attract investment in clinical trials in Europe.”
- Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon, on the potential of the JCA to promote a competitive life sciences sector in Europe.
Source: Event Report--The First Joint Clinical Assessments for ATMPs: What's Next?
- Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon, on the potential of the JCA to promote a competitive life sciences sector in Europe.
Source: Event Report--The First Joint Clinical Assessments for ATMPs: What's Next?
HTA by the numbers
2 of 25
The European Commission recently announced that the first two Joint Clinical Assessments (JCAs) are underway, evaluating a medicinal product for the treatment of pediatric low-grade glioma (led by health technology assessment [HTA] agencies from Ireland and Germany) and an advanced therapy medicinal product (ATMP) for the treatment of melanoma (led by HTA agencies from France and Poland). The Member State Coordination Group on HTA (HTACG) has previously estimated that 25 JCAs will be started in 2025.
Source: Health Technology Assessment: First Joint Clinical Assessments Begin
Source: Health Technology Assessment: First Joint Clinical Assessments Begin
Connect with our team
Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.
